CLINICAL RESEARCH
Europace(2015)17,1276–1281
doi:10.1093/europace/euv039 Pacingandresynchronizationtherapy
A randomized study of remote monitoring and
fluid monitoring for the management of patients
with implanted cardiac arrhythmia devices
Lars Lu¨thje*, Dirk Vollmann,Joachim Seegers, Christian Sohns, Gerd Hasenfuß,
and Markus Zabel
DivisionofCardiologyandPneumology,HeartCenter,UniversityofGo¨ttingen,Robert-Koch-Str.40,Go¨ttingen37075,Germany
Received5January2015;acceptedafterrevision3February2015;onlinepublish-ahead-of-print17May2015
Aims Onlylimitedcomparativedataexistonthebenefitsoffluidmonitoring(FM)combinedwithremotemonitoring(RM)
regardingmorbidityandmortalityofheartfailure(HF)patients.Thisprospectivesingle-centrerandomizedpilotstudy
aimedtoestimatetheinfluenceofRMincombinationwithFMonHFhospitalizationsaswellasventriculartachyarrhyth-
miasandmortality.
.....................................................................................................................................................................................
Methods Patientswithstandardindicationforimplantablecardioverterdefibrillator(ICD)orcardiacresynchronizationtherapy
andresults anddefibrillatorwereimplantedwithdevicescapableofRMandFM,andwerefollowedfor15months.Subjectswere
randomlyallocatedtoRMincludingOptiVolandpredefinedmanagementofalerts(remotegroup),orstandardin-
officevisitsevery3months(controlgroup).Atotalof176patients(77%male;66+12years;leftventricularejection
fraction(LVEF)32+11%;ischemiccardiomyopathy50%;CRTdevice50%;primaryprevention85%)wereanalysed.
CoxproportionalhazardanalysisonthetimetofirstHF-relatedhospitalizationshowedahazardratioof1.23[0.62–
2.44](P¼0.551)favouringthecontrolgroup.Intheremotegroup,13patients(15%)experiencedICDshocksvs.10
patients (11%) in the control group (P¼0.512). The average time to first ICD shock was 212+173 days in the
remotearmand212+143daysinthecontrolarm(P¼0.994).TheKaplan–Meierestimateofmortalityafter1year
was8.6%(eightdeaths)intheremotegroupvs.4.6%inthecontrolgroup(sixdeaths;P¼0.502).
.....................................................................................................................................................................................
Conclusion Inasingle-centrerandomizedpilotstudyofRMincombinationwithFM,nosignificantinfluenceonHF-relatedhospita-
lizations,ICDshocks,ormortalitywasfound.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Heartfailure † Cardiacdecompensation † Fluidmonitoring † OptiVolfluidindex † Remotemonitoring †
Telemedicine
Introduction device. While first investigations showed promising results,2–4
largerandrandomizedtrialsrevealeddisappointingoutcomes.5,6A
Heartfailure(HF)isahighlyprevalentdiseasewithsubstantialmor- validoptionforimprovingthefluidmonitoring(FM)featuremight
bidity and mortality. Consequently, the disease is an important be additional use of remotemonitoring (RM), astimely measures
healthcareissuewiththemajorityofcostsattributedtoHFhospita- ofwirelessfluidoverloadalertsmayavertcardiacdecompensation
lizations.1 Efforts continue to detect fluid accumulation early to andHFhospitalization.Sofar,onlylimited comparativedata exist
preventhospitalizationforacutecardiacdecompensation.Asclinical onthebenefitsofwirelessFMregardingmorbidityandmortalityof
signsofHFdeteriorationareoftenunreliable,device-basedsensors HFpatients.
havebeendevelopedforthecontinuousmonitoringofthepatients’ Thisprospectivesingle-centrerandomizedpilotstudyaimedto
HF status. One such approachisthe continuous measurement of evaluatetheinfluenceofRMincombinationwithwirelessFMusing
intrathoracic impedance with an implanted cardiac arrhythmia OptiVolalerts(Medtronic,Minneapolis,MN,USA)ontimetofirst
*Correspondingauthor.Tel:+49551398922;fax:+495513920900,E-mailaddress:larsluethje@med.uni-goettingen.de
PublishedonbehalfoftheEuropeanSocietyofCardiology.Allrightsreserved.&TheAuthor2015.Forpermissionspleaseemail:journals.permissions@oup.com.
Downloaded
from
by
guest
on
November
15,
2015
Randomizedstudyofremotemonitoringandfluidmonitoring 1277
remainedunchangedduringfollow-up.Incaseofanautomaticalerttrans-
What’snew? mission,apre-specifiedclinicaldecisionroutinewasactivatedasdetailed
inFigure1.Evaluationoftheclinicalstatusofthepatientsincludedassess-
† So far only few tools for monitoring patients with chronic
mentofsymptomssuchasdyspnoea,weightgain,oedema,activitystatus,
heartfailure(HF)toidentifyearlycardiacdeteriorationexist.
andfatigue.
† Continuousmeasurementofintrathoracicimpedancewithan
Inthecontrolgroup,standardin-officevisitswereperformedevery3
implantedcardiacarrhythmiadevicemightimprovetheman-
months.
agementofHFpatients.
† So far data investigating the impedance measurement are Aims
conflicting.
TheaimofthisstudywastoestimatetheinfluenceofRMincombination
† Furthermore,onlylimitedcomparativedataexistontheben-
withFMusingOptiVolalertsonthetimetofirstHF-relatedhospitaliza-
efitsoffluidmonitoring(FM)combinedwithremotemonitor- tionaswellastachyarrhythmiaoccurrenceandmortalitywhencom-
ingregardingmorbidityandmortalityofHFpatients. paredwithstandardclinicalcare.
† Thisprospectiverandomizedpilotstudyaddsimportantinfor-
mationtothevalueofdevice-basedFMcombinedwithteleme- Dataanalysis
dicalsupportfortheearlydetectionofHFdecompensationto Statistical analysis was performed using commercial software. Unless
reducehospitalizations. otherwise noted, all data are reported as mean+SD. Differences
† OurdatashownosignificantinfluenceonHFrelatedhospita- inbaselinecharacteristicswereevaluatedusingaStudent’st-test,ax2
lizations,ICDshocks,ormortality test, or a Fisher’s exact test, where appropriate. For time to first
HF-relatedhospitalization,timetofirstICDshock,andtimetodeatha
Coxproportionalhazardanalysis,andaKaplan–Meiersurvivalanalysis
withlog-ranktestwereperformed.AP-valueof,0.05wasconsidered
statisticallysignificant.
HF-relatedhospitalization as well astachyarrhythmia occurrences
andmortalitywhencomparedwithstandardclinicalcare.
Results
Methods
Patientcharacteristics
Patientselection BetweenDecember2007andApril2011,atotalof180patientswere
included.Twopatientswerenotrandomizedbecausetheplanned
Adetaileddescriptionofthestudydesignhasbeenpublishedpreviously.7
devicewaseventuallynotimplanted.Anothertwopatientswithdrew
Inbrief,patientsaged.18yearsinneedforanimplantablecardioverter
defibrillator(ICD)orcardiacresynchronizationtherapyanddefibrillator theirconsentsoonafterimplantation.Thus,afterexclusionofthe
(CRT-D)accordingtocurrentguidelinesorpatientswithapreviously described4patients,atotalof176patientswereanalysed.Baseline
implanteddevicewithoutFMfeatureandareplacementindicationfor characteristicsaresummarizedinTable1.Atinclusion,therewere
battery depletion were included in the study after written informed 73patients(83.9%)intheremotearminfunctionalNYHAclassII
consent.HeartfailureorahistoryofdecompensatedHFhospitalization orhigher,comparingwith82patients(93.2%)inthecontrolarm,re-
wasnotaprerequisiteforinclusion.Medtronicdeviceswithtelemonitor- spectively.ACRTdevicewasimplantedinhalfofthepatientsinboth
ingcapabilitiesandOptiVolalert(ConcertoorConsultaCRT-D,Virtu-
groups.
osoorSecuraICD-DR)wereused.Exclusioncriteriawerepermanent
atrialfibrillation,alifeexpectancy≤15months,pregnancy,andparticipa-
OptiVolalerts,urgentvisits,and
tioninanotherstudy.
hospitalizations
OptiVolfluidindex A total of 174 OptiVol alerts (94 in CRT patients and 80 in ICD
TheOptiVolfluidindexhasbeendescribedindetailelsewhere.4,8Inbrief, patients)in68patients(35patientswithCRTand33patientswith
thedevicedeterminesarepresentativeimpedancedailyandcompares ICD)occurredintheremotegroup(i.e.78%oftheremotegroup
this with a roving reference value. Whenever daily impedance drops patients). Of these, 93 alerts (54 in CRT patients and 39 in ICD
below the reference, a cumulative, absolute difference is calculated, patients)wereclassifiedastruepositivebasedonclinicalassessment
andcalledfluidindex.Crossingaprogrammablethresholdindicatesa ofthecircumstancesbutnotonthebasisofalaterrequiredhospital-
possiblefluidoverloadofthepatient,andanOptiVolalertistriggered.
ization.In74ofthesecases,ambulatory patientmanagementwas
clinicallypossible,whereasin19caseshospitalizationwasrequired.
Studydesignandprotocol
Alldecisionsweremadebytheinvestigators.
Thisrandomized,single-centre,prospectivepilotstudycomplieswiththe
One additional hospitalization occurred without prior OptiVol
DeclarationofHelsinki,andthestudyprotocolwasapprovedbytheIn-
alert.Thus,intotal,20patientsintheremotegroupand22patients
stitutionalEthicsCommittee.Allpatientsgavetheirwritteninformed
in the control group were hospitalized for worsened HF during
consent.PatientsreceivingCRT-DorDR-ICDimplantsorreplacements
the follow-up period. As shown in Figure 2, Cox proportional
wererandomizedtoRMincludingOptiVolON(remotearm)vs.RMOFF
hazard analysis on the time to first HF-related hospitalization
(standardarm)andfollowedfor15months.Inbothgroups,theaudible
OptiVol alert was disabled. Patients in the remote arm, however, showed a hazard ratio of 1.231 ([0.621–2.438]; P¼0.551). The
were connected to the Medtronic CareLink network. The OptiVol meannumberofemergencydepartmentvisitswasnotsignificantly
fluidindexthresholdwassettothenominal60Vatimplantationand different between the two groups (RM group 0.10+0.25 vs.
Downloaded
from
by
guest
on
November
15,
2015
1278 L.Lu¨thjeetal.
controlgroup0.10+0.23;P¼0.7295).Themeannumberofurgent Ventriculartachyarrhythmiasand
carevisits,however,differedstatisticallysignificantwith0.30+0.50 mortality
visitsintheremotegroupand0.10+0.30visitsinthecontrolgroup
(P¼0.0332). Intheremotegroup,13patients(15%)experiencedICDshocksvs.
10patients(11%)inthecontrolgroup.Inappropriateshockswere
deliveredinfourcasesintwopatients(2%)intheremotearmand
intwocasesintwopatients(2%)inthecontrolarm.Reasonsforin-
appropriatetherapywereatrialfibrillationwithfastventricularrate
OptiVol
(n¼3),sinustachycardia(n¼1),leadfailure(n¼1),andelectro-
alert cauterizationuponnon-cardiacsurgery(n¼1).Theaverage time
tofirstICDshockwas212+173daysintheRMarmand212+
Review report of (cid:129) Cardiac compass
143daysinthecontrolarm(P¼0.994).Kaplan–Meieranalysisfor
(cid:129) Heart failure timetofirstICDshockrevealednosignificantdifferencebetween
thetwogroups(P¼0.512)(Figure3).
Phone patient and evaluate: Atotalofeightpatientsintheremotearmwhencomparedwithsix
(cid:129) Patient clinical status
(cid:129) Optivol fluid index chart patientsinthecontrolarmdiedduringfollow-up.Ineachgroup,one
death was classified as sudden cardiac and three deaths as non-
sudden cardiac death. Non-cardiac deaths occurred once in the
POSITIVE False positive remotegroupandtwiceinthecontrolgroup.Threedeathsinthe
OptiVol alert OptiVol alert
remote group could not reliably be classified. The Kaplan–Meier
estimateofall-causemortalityafter1yearwas8.6%intheremote
NO SIGNS for clinical SIGNS for clinical No action required group vs. 4.6% in the control group. No significant difference
decompensation decompensation
could be observed for time to death between the two groups
(P¼0.502)(Figure4).
-Increase loop diuretic
dose for 50%
Admit patient to hospital
-Patient remains outpatient immediately
-Patients weighs her/himself Discussion
daily
Themainfindingofourstudyisthatdevice-basedFMcombinedwith
Figure1 Pre-specifiedclinicaldecisionroutineactivatedbyan
RMhasnofavourableeffectwhencomparedwithstandardclinical automaticOptiVolalerttransmission.(Reprintedwithpermission
careonthetimetofirstHF-relatedhospitalizationaswellastachyar-
fromRef.7.)
rhythmiaoccurrences,ormortality.
Table1 Patientcharacteristics
All(n5176) Remote(n587) Control(n589) P-value
...............................................................................................................................................................................
#Male(%) 136(77.3%) 70(80.5%) 66(74.2%) 0.3702
Meanage(+SD) 65.9(+12.0) 66.0(+12.0) 65.9(+12.1) 0.9485
MeanLVEF(+SD) 31.9(+10.8) 32.7(+11.4) 31.1(+10.2) 0.328
MeanQRSduration(+SD) 136(+129) 149(+179) 123(+38) 0.2811
#LBBB(%) 66(37.5%) 31(35.6%) 35(39.3%) 0.6429
#RBBB(%) 13(7.4%) 5(5.7%) 8(9.0%) 0.5664
#NYHAI(%) 19(10.9%) 13(14.9%) 6(6.8%) 0.0945
#NYHAII(%) 80(45.7%) 40(46.0%) 40(45.5%) 1
#NYHAIII(%) 71(40.6%) 32(36.8%) 39(44.3%) 0.3566
#NYHAIV(%) 4(2.3%) 1(1.1%) 3(3.4%) 0.6207
#Ischaemiccardiomyopathy(%) 90(51.1%) 51(58.6%) 39(43.8%) 0.0521
#Coronaryarterydisease(%) 94(53.4%) 48(55.2%) 46(51.7%) 0.6536
#Hypertension(%) 118(67.0%) 62(71.3%) 56(62.9%) 0.2642
#Diabetes(%) 48(27.3%) 24(27.6%) 24(27.0%) 1
#Persist./parox.AF(%) 52(29.5%) 22(25.3%) 30(33.7%) 0.2496
#CRTICD(%) 88(50.0%) 44(50.6%) 44(49.4%) 1
#Primaryprevention(%) 149(84.7%) 71(81.6%) 78(87.6%) 0.3006
#Secondaryprevention(%) 27(15.3%) 16(18.4%) 11(12.4%) 0.3006
Downloaded
from
by
guest
on
November
15,
2015
reported a substantial portion of false-positive detections.2–4
Anotherstudyinvestigatingthealertalgorithmwasabletodemon-
strateareductionofHFhospitalizations9inanon-randomizedcom-
parison.However,thesepositiveresultscouldnotbeconfirmedin
subsequent trials. In the prospective observational SENSE-HF
study,sensitivityandpositivepredictivevalueofimpedancemonitor-
ingwereconsiderablylow.5IntherandomizedcontrolledDOT-HF
study, the use of impedance measurement did not reduce deaths
andHFhospitalizations.6
Importantly,all oftheinvestigationsmentionedabove havenot
combinedFM(withoutaudiblealert)withRMforthetimelydetec-
tionofHFdeterioration.Thiscombinationmayovercomeshortcom-
ingsoftheimpedancemeasurementwiththeaudiblealert,suchas
frequent unnecessary outpatient clinic visits due to inadequate
alerts, or some overreaction of the treating physician faced with
thepatients’expectation,whomaybeconcernedbyanaudiblealert.
AnotherimportantadvantageofadditionalRMmightbeafurtherre-
ductionofthetimefromthedevicealerttotheclinicalactiontakento
prevent manifest decompensation with hospitalization.10,11 Import-
antly,largerstudiesinvestigatingremotetelemedicalsupportforHF
1.0
management but not involving automatic transmissions could not
0.8 showabenefit.12,13Veryrecently,preliminarydataoftheIN-TIME
studyrevealedasignificantreductionofall-causemortalityandcardio-
0.6
vascularmortalityintheRMarmwhencomparedwithcontrols.14The
combineduseofimpedancemeasurementandRMwasinvestigatedin
theEVOLVOstudy,demonstratingreducedemergencydepartment
orurgentin-officevisitsby35%withoutaffectinghospitalizations.10
Inourstudy,wewerenotabletoshowabenefitofimpedance
monitoring combined with RM when compared with a control
groupdespiteapredefinedmanagementroutineofalerts.Incontrast
totheEVOLVOstudy,10ourstudyshowedmoreurgentcarevisitsin
theremotegroupwhencomparedwiththecontrols.Althoughwe
classified 93 OptiVol alerts as true positive, and ≈80% of these
alerts were manageable without the need for hospitalization, this
did not translate into a reduction of HF-related hospitalizations
when compared with standard treatment. Several reasons may
account for this. First, as HF hospitalizations could not be used
anymore as a gold standard when aiming to avoid them, not all
alerts may have been correctly classified. Secondly, the natural
courseofimpendingHFdeteriorationmaynotalwaysleadtomani-
festcardiacdecompensation,butalsotospontaneousimprovement
ofHFandreturntostableconditions.Inthiscontext,theaimofthe
studyofanearlyinterventiontopreventhospitalizationmighthave
beencounteractedbyearlydetectionsofHFdecompensationneces-
sitatingin-patienttreatmentintheremotegroup.Thesamepatient
inthecontrolgroupmighthave spontaneouslyimprovedwithout
the need for hospitalization and unnoticed by a physician. Finally,
cardiacdecompensationmaybemorecomplexthantheassumption
of a prolonged subclinical period of linear HF deterioration be-
foremanifestdecompensation,thusmeasurablewithintrathoracic
impedance.15Indeed,inourstudy19ofthepositivealertpatients
wereclinicallydiagnosedasanalreadymanifestcardiacdecompensa-
tionthatrequiredhospitalization.Thesecasessuggestashortersub-
clinicalperiodbeforedecompensationwithoutagenuinechanceto
While the first small or observational studies investigating intervene.
intrathoracic impedance measurement revealed a sensitivity of ResultsreportedbySinghetal.16suggestedthatworseningclinical
60–77%fordetectionofaHFrelatedfluidaccumulation,theyalso conditions such as hospitalization for HF are associated with an
ytilibaborp
lavivruS
1.0
0.8
0.6
0.4
0.2
+ Censored
0.0
1 89 83 79 72 58 31
2 85 69 67 66 61 28
0.00 0.25 0.50 0.75 1.00 1.25
Time to first shock (years)
Randomization 1: Control 2: Remote
Figure3 Kaplan–MeiereventprobabilitiesfortimetofirstICD
shock(P-valuelog-ranktest¼0.512).
ytilibaborp
lavivruS 0.4
0.2 + Censored
0.0
1 89 83 79 75 70 56
2 87 70 66 63 61 47
0.00 0.25 0.50 0.75 1.00 1.25
Time to first HF related hospitalization (years)
Randomization 1: Control 2: Remote
Figure 2 Kaplan–Meier event probabilities for time to first
HF-relatedhospitalization(P-valuelog-ranktest¼0.551).
1.0
0.8
0.6 ytilibaborp
lavivruS
Randomizedstudyofremotemonitoringandfluidmonitoring 1279
0.4
0.2
+ Censored
0.0
1 89 86 86 81 77 63
2 87 78 77 74 74 57
0.00 0.25 0.50 0.75 1.00 1.25
Time to death (years)
Randomization 1: Control 2: Remote
Figure 4 Kaplan–Meier event probabilities for time to death
(P-valuelog-ranktest¼0.502).
Downloaded
from
by
guest
on
November
15,
2015
1280 L.Lu¨thjeetal.
increasedriskofICDshockdelivery.Furthermore,anincreasedrisk Acknowledgements
for first and recurrent HF events after ICD discharge has been
WethankDanielBecker(MedtronicInc.)forstatisticalanalysisand
found.17Severalinvestigationshavealsoshownthatappropriateas
SabineBusseforinterrogationandmanagementofstudypatients.
wellasinappropriateICDdischargesnegativelyimpactonmortal-
ity.18Thus,improvementofHFstatusaswellasearlydetectionof
Funding
device-relatedproblemsusingtelemonitoringshouldbecapableof
impactingontherateofinappropriateandappropriateICDshockde- ThestudywasfundedbytheMedtronicInc.
liveriesontheonehand.Ontheotherhand,areductionofICDdis-
Conflictofinterest:L.L.hasreceivedresearchandtravelsupportfrom
charges could positively influence HF-related hospitalization and
Medtronic.D.V.hasreceivedlecturefeesandtravelsupportfromMed-
mortality.Inthepresentstudy,however,wewerenotabletoseea
tronic.J.S.hasreceivedtravelsupportfromMedtronic.C.S.andG.H.:
significantdifferenceofICDshockdeliveriesbetweentheremote nonedeclared.M.Z.hasreceivedresearchfundingfromMedtronicin-
andthecontrolarms.Thisisinlinewithpreviouslypublisheddata cludingthisstudy,aswellasfromBiotronikandBostonScientific,has
fromLandolinaetal.10.However,intheirstudyaswellasinours, receivedlecturefeesandtravelgrantsupportfromMedtronic,Boston
thenumberofeventsmightnothavebeenhighenoughforsufficient Scientific,andBiotronik,andhasservedonadvisoryboardsforBiotronik,
discrimination. BostonScientific,andMedtronic.
So far, only limited data are available concerning mortality and
intrathoracicimpedancemonitoringortelemonitoringuse.Previous References
studiesinvestigatingtheimpactofimpedancemonitoringortelemo- 1. HeidenreichPA,AlbertNM,AllenLA,BluemkeDA,ButlerJ,FonarowGCetal.Fore-
nitoringonHFhospitalizationsordeathrevealednosignificantdiffer- castingtheimpactofheartfailureintheUnitedStates:apolicystatementfromthe
encesbetweenthecontrolandtreatmentgroups.6,12Thesestudies AmericanHeartAssociation.CircHeartFail2013;6:606–19.
2. AbrahamWT,ComptonS,HaasG,ForemanB,CanbyRC,FishelRetal.FastStudy
areinlinewithourdata,aswewereunabletodemonstratemortality Investigators.Intrathoracicimpedancevsdailyweightmonitoringforpredicting
differences between the treatment and control groups. As men- worsening heart failure events: results of the Fluid Accumulation Status Trial
tionedearlier,recentlyresultsfromtheIN-TIMEtrial14werepre- (FAST).CongestHeartFail2011;17:51–5.
3. VollmannD,Na¨geleH,SchauerteP,WiegandU,ButterC,ZanottoGetal.InSync
sented. A total of664patientswith implantedcardiacarrhythmia SentryObservationalStudyInvestigators.Clinicalutilityofintrathoracicimpedance
devices were randomly assigned to telemonitoring or standard monitoringtoalertpatientswithanimplanteddeviceofdeterioratingchronicheart
failure.EurHeartJ2007;28:1835–40.
careandfollowedfor12months.Asignificantreductionoftotalmor-
4. YuCM,WangL,ChauE,ChanRH,KongSL,TangMOetal.Intrathoracicimpedance
talityandcardiovascularmortalityof(cid:4)65%betweenthetwogroups monitoringinpatientswithheartfailure:correlationwithfluidstatusandfeasibilityof
wasobserved.Thisriskreductionduring12monthsoffollow-upis earlywarningprecedinghospitalisation.Circulation2005;112:841–8.
5. ConraadsVM,TavazziL,SantiniM,OlivaF,GerritseB,YuCMetal.Sensitivityand
difficulttocomprehendinthelightofourresults,evenifourstudy
positivepredictivevalueofimplantableintrathoracicimpedancemonitoringasapre-
included only about a quarter of the patients and was as a pilot dictorofheartfailurehospitalisations:theSENSE-HFtrial.EurHeartJ2011;32:
studynotpoweredformortalityanalysis.Currently,twolargetrials 2266–73.
6. vanVeldhuisenDJ,BraunschweigF,ConraadsV,FordI,CowieMR,JondeauG
aimedatfurtherelucidatingtheroleofRMcombinedwithFMare et al. DOT-HF Investigators. Intrathoracic impedance monitoring, audible
underway.19,20 patientalerts,andoutcomeinpatientswithheartfailure.Circulation2011;124:
1719–26.
7. ZabelM,VollmannD,Lu¨thjeL,SeegersJ,SohnsC,ZenkerDetal.RandomizedClin-
Limitations
icalevaluatiONofwirelessfluidmonitoriNgandrEmoteICDmanagemenTusing
OptiVolalert-basedpredefinedmanagementtoreducecardiacdecompensation
Themainlimitationofourstudyisthenumberofpatientsincluded.As
and health care utilization: the CONNECT-OptiVol study. Contemp Clin Trials
nosignificantdifferencesbetweenthetreatmentgroupswerefound, 2013;34:109–16.
ourresultsshouldbeinterpretedwiththecautionthattheymaybe 8. Lu¨thjeL,VollmannD,DrescherT,SchottP,ZenkerD,HasenfussGetal.CIntrathor-
acicimpedancemonitoringtodetectchronicheartfailuredeterioration:relation-
due to under-powering. However, we have conducted a uniform
shiptochangesinNT-proBNP.EurJHeartFail2007;9:716–22.
single-centre prospective, randomized pilot study with (cid:4)180 9. CatanzaritiD,LunatiM,LandolinaM,ZanottoG,LonardiG,IacopinoSetal.
patients included, thus hypothesis generating conclusions may be Monitoringintrathoracicimpedancewithanimplantabledefibrillatorreduces
hospitalisationsinpatientswithheartfailure.PacingClinElectrophysiol2009;32:
drawnfromourdata.Anotherpotentiallimitationisthesingle-centre
363–70.
design of our study. However, the uniform response by a small 10. LandolinaM,PeregoGB,LunatiM,CurnisA,GuenzatiG,VicentiniAetal.Remote
experiencedstudygroupreducestheriskofheterogenousresponse monitoringreduceshealthcareuseandimprovesqualityofcareinheartfailure
patientswithimplantabledefibrillators:theevolutionofmanagementstrategiesof
toOptiVolalerts,whichisunavoidableinamulticentretrial.Thisway,
heartfailurepatientswithimplantabledefibrillators(EVOLVO)study.Circulation
riskofaheterogeneousresponseasreasonforthenegativeresultcan 2012;125:2985–92.
besubstantiallyreduced. 11. AbrahamWT.Diseasemanagement:remotemonitoringinheartfailurepatients
with implantable defibrillators, resynchronization devices, and haemodynamic
monitors.Europace2013;15(Suppl1):i40–6.
12. ChaudhrySI,MatteraJA,CurtisJP,SpertusJA,HerrinJ,LinZetal.Telemonitoringin
Conclusion
patientswithheartfailure.NewEnglJMed2010;363:2301–9.
13. KoehlerF,WinklerS,SchieberM,SechtemU,StanglK,Bo¨hmMetal.Telemedical
Thedataofthissingle-centreprospectiverandomizedpilottrialdo InterventionalMonitoringinHeartFailureInvestigators.Impactofremotetelemedi-
cal management on mortality and hospitalisations in ambulatory patients with
notsupporttheuseofRMcombinedwithintrathoracicimpedance
chronicheartfailure:thetelemedicalinterventionalmonitoringinheartfailure
monitoring in patients implanted with cardiac arrhythmia devices study.Circulation2011;123:1873–80.
for the reduction of hospitalizations, tachyarrhythmia occurrence 14. HindricksG,TaborskyM,GliksonM,HeinrichU,SchumacherB,KatzAetal.
Implant-based multiparameter telemonitoring of patients with heart failure
ormortality.Thisdataneedtobeconfirmedinlargerandomized
(IN-TIME):arandomisedcontrolledtrial.Lancet2014;384:583–90.
trials. 15. UdelsonJE.T.M.I.(Toomuchinformation)?Circulation2011;124:1697–9.
Downloaded
from
by
guest
on
November
15,
2015
Randomizedstudyofremotemonitoringandfluidmonitoring 1281
16. SinghJP,HallWJ,McNittS,WangH,DaubertJP,ZarebaWetal.Factorsinfluencing therapiesonmortality:asystematicreviewandmeta-analysis.CircArrhythmElectro-
appropriatefiringoftheimplanteddefibrillatorforventriculartachycardia/fibrilla- physiol2014;7:164–70.
tion:findingsfromtheMulticenterAutomaticDefibrillatorImplantationTrialII 19. BurriH,QuesadaA,RicciRP,BorianiG,DavinelliM,FavaleSetal.TheMOnitoring
(MADIT-II).JAmCollCardiol2005;46:1712–20. ResynchronizationdEvicesandCARdiacpatiEnts(MORE-CARE)study:rationale
17. GoldenbergI,MossAJ,HallWJ,McNittS,ZarebaW,AndrewsMLetal.Multicenter anddesign.AmHeartJ2010;160:42–8.
Automatic Defibrillator Implantation Trial (MADIT) II Investigators. Causes and 20. BrachmannJ,Bo¨hmM,RybakK,KleinG,ButterC,KlemmHetal.Fluidstatusmon-
consequencesofheartfailureafterprophylacticimplantationofadefibrillatorinthe itoringwithawirelessnetworktoreducecardiovascular-relatedhospitalizations
multicenterautomaticdefibrillatorimplantationtrialII.Circulation2006;113:2810–7. andmortalityinheartfailure:rationaleanddesignoftheOptiLinkHFStudy(Opti-
18. TanVH,WiltonSB,KuriachanV,SumnerGL,ExnerDV.Impactofprogramming mizationofHeartFailureManagementusingOptiVolFluidStatusMonitoringand
strategiesaimed atreducingnonessential implantable cardioverter defibrillator CareLink).EurJHeartFail2011;13:796–804.
Downloaded
from
by
guest
on
November
15,
2015
